Interim Results from the International Trial
of Second Sight’s Visual Prosthesis
Mark S. Humayun, MD, PhD,1 Jessy D. Dorn, PhD,2 Lyndon da Cruz, MD, PhD,3 Gislin Dagnelie, PhD,4
José-Alain Sahel, MD,5 Paulo E. Stanga, MD,6 Artur V. Cideciyan, PhD,7 Jacque L. Duncan, MD,8 Dean Eliott, MD,9
Eugene Filley, PhD,10Allen C. Ho, MD,11 Arturo Santos, MD,12 Avinoam B. Safran, MD,13 Aries Arditi, PhD,14
Lucian V. Del Priore, MD,4,15 Robert J. Greenberg, MD, PhD,2 for the Argus II Study Group*1
Purpose: This study evaluated the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc.,
Sylmar, CA) in blind subjects with severe outer retinal degeneration.
Design: Single-arm, prospective, multicenter clinical trial.
Participants: Thirty subjects were enrolled in the United States and Europe between June 6, 2007, and
August 11, 2009. All subjects were followed up for a minimum of 6 months and up to 2.7 years.
Methods: The electronic stimulator and antenna of the implant were sutured onto the sclera using an encircling
silicone band. Next, a pars plana vitrectomy was performed, and the electrode array and cable were introduced into
the eye via a pars plana sclerotomy. The microelectrode array then was tacked to the epiretinal surface.
Main Outcome Measures: The primary safety end points for the trial were the number, severity, and relation
of adverse events. Principal performance end points were assessments of visual function as well as performance
on orientation and mobility tasks.
Results: Subjects performed statistically better with the system on versus off in the following tasks: object localization
(96% of subjects), motion discrimination (57%), and discrimination of oriented gratings (23%). The best recorded visual
acuity to date is 20/1260. Subjects’ mean performance on orientation and mobility tasks was significantly better when the
system was on versus off. Seventy percent of the patients did not have any serious adverse events (SAEs). The most
common SAE reported was either conjunctival erosion or dehiscence over the extraocular implant and was treated
successfully in all subjects except in one, who required explantation of the device without further complications.
Conclusions: The long-term safety results of Second Sight’s retinal prosthesis system are acceptable, and
most subjects with profound visual loss perform better on visual tasks with system than without it.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Ophthalmology 2011;xx:xxx © 2011 by the American Academy of Ophthalmology.
*Group members listed online in Appendix 1.
Several different treatment avenues using biologic and bioelectronic approaches have been proposed to restore sight to
the blind.1– 4 Some of the major challenges for bioelectronic
implants include long-term stable performance of the implanted electronics, as well as a safe surgical implantation
procedure. Previous studies have shown that electrical stimulation of the retinal ganglion cell side (epiretinal stimulation) can produce discrete phosphenes and that spatial resolution and partial restoration of vision is possible.5–13
Herein, from an ongoing international clinical trial evaluating the Argus II Retinal Prosthesis System (Second Sight
Medical Products, Inc., Sylmar, CA), is reported the experience with 45.6 cumulative subject-years in 30 subjects
implanted at 10 clinical centers.
Patients and Methods
Statement of Compliance
This multicenter feasibility study for Second Sight’s retinal prosthesis system is being conducted in accordance with the Declara© 2011 by the American Academy of Ophthalmology
Published by Elsevier Inc.
tion of Helsinki and the national regulations for medical device
clinical trials in the countries in which the study is being conducted. The study has been approved by the national ministries of
health in these countries and the ethics committees or institutional
review boards of participating institutions. All subjects signed
informed consent to participate. The clinical trial is posted on
www.clinicaltrials.gov, trial registration number NCT00407602.
Purpose of Study and Description of Subjects
The study is a single-arm, prospective, unmasked study to evaluate
the safety and usefulness of the prosthesis in providing functional
vision to blind subjects with end-stage outer retinal degenerations.
A total of 32 subjects have been implanted with the prosthesis. The
first 2 subjects were part of a pilot study in Mexico (the first
country to grant regulatory approval for clinical use); because
these subjects received a significantly different device (the electrode array was placed outside of the macula), this report focuses
on the 30 subjects who received an electrode array that could be
placed at least partly in the macular region. These 30 subjects were
50 years of age or older (18 or older at some clinical sites) with a
diagnosis of retinitis pigmentosa (or other outer retinal degeneration at some sites; 1 participant had Leber congenital amaurosis
ISSN 0161-6420/11/$–see front matter
doi:10.1016/j.ophtha.2011.09.028
1
Ophthalmology
Volume xx, Number x, Month 2011
and 1 had choroideremia) with remaining vision of bare or no light
perception (visual acuity worse than 2.9 logarithm of the minimum
angle of resolution [logMAR] in both eyes). All subjects had a
history of useful form vision. Exclusion criteria addressed any
inability to implant the device physically, concurrent complicating
ocular pathologic features, and any inability to commit to the
expectations and duration of the study. Refer to www.clinicaltrials.
gov for full subject selection criteria.
Subjects had a median age of 57.5⫾9.9 years (range, 27–77
years) at the time of implantation, and all but 1 subject were at
least 45 years of age. Thirty percent of subjects were female and
70% were male. Some subjects (33%) had undergone previous
cataract removal surgery in the implanted eye, and 1 subject had
had several previous ocular surgeries in the implanted eye (prior
pars plana vitrectomy to clear vitreous debris and subconjunctival
placental tissue injections). The last 15 subjects were implanted
with a modified device that was slightly re-engineered to have a
more flexible cable and an electrode array that allowed closer
apposition of the electrodes to the underlying retina. All subjects
were followed up for a minimum of 6 months and up to 2.7 years.
Description of Device
The Argus II Retinal Prosthesis System consists of an active
implantable device surgically implanted on and in the eye and an
external unit worn by the user. The external unit consists of a small
camera and transmitter mounted on glasses and a video processor
and battery worn on the belt or a shoulder strap (Fig 1A).
The implanted portion (Fig 1B) consists of a receiving and
transmitting coil and electronics case that are fixed to the sclera
outside of the eye and an electrode array (60 electrodes) that is
positioned surgically onto the surface of the retina by a retinal tack.
The electrode array is connected to the electronics case by a
metallized polymer ribbon cable that penetrates the sclera in the
pars plana. The camera captures video and sends the information
to the processor, which converts the image to electronic signals
that are then sent to the transmitter coil on the glasses. The
episcleral implanted receiver coil and antenna wirelessly receives
these data and sends the signals via the ribbon cable to the
electrode array, where electrical stimulation pulses are emitted.
The spatially controlled microelectrode electrical stimulation of
the retinal cells induces cellular responses in the retina that travel
through the optic nerve to the central visual system, resulting in
visual percepts.
Although magnification or zoom is possible in the system, for
this study, the field of view of the camera was cropped to match the
predicted visual field of the array on the retina (assuming 1° visual
angle ⫽ 300 m on the retina).14 The cropped image then was
downsampled to 10⫻6 pixels. The pixels were mapped 1:1 onto
the electrodes of the implanted array, so the chosen field of view
of the camera matched the field of view of the array—
approximately 20° on the diagonal.
Surgery
At the start of the implant procedure, 8 mg dexamethasone (to
reduce inflammation) and 1 g cefazolin (or equivalents) were
administered by intravenous injection. In phakic eyes, the lens was
removed via clear cornea phacoemulsification (with the exception
of pars plana lensectomy in 1 subject). Next, a 360° limbal conjunctival peritomy was performed followed by isolating the rectus
muscles using 2⫺0 black silk.
The coil was placed temporally on the globe and was centered
under the lateral rectus muscle. The electronics package was
centered in the superior temporal quadrant. The inferior part of the
scleral band was passed under the inferior and the medial rectus
2
muscles, and the superior portion of the band was passed under the
superior rectus muscle. The implant was fixed to the eye via
sutures passed through suture tabs on the implant in both temporal
quadrants and with the use of mattress sutures around the encircling band in the nasal quadrants with the Watzke sleeve (Labtician Ophthalmics, Inc., Oakville, Canada) positioned in the supranasal quadrant.
Core and peripheral vitrectomies were performed and were
followed by dissection of any epiretinal membrane in the area
where the surgeon intended to tack the array. The microelectrode
array then was inserted through a temporal sclerotomy (approximately 5 mm in width) and was placed onto the retina in the
macula and then tacked using a custom retinal tack (Second Sight
Medical Products, Inc.). The extraocular portion of the cable was
sutured to the sclera and all sclerotomies were sutured.
An allograft (Tutoplast; IOP, Inc., Costa Mesa, CA), or a
suitable alternative in countries where allografts were not permitted, was sutured and draped over the electronics package to reduce
the likelihood of conjunctival irritation. Finally, the Tenon’s capsule and the conjunctiva were sutured.
At the end of the surgery, 2 mg dexamethasone, 100 mg
cefazolin, and 2 ml lidocaine (or equivalents) were injected under
the conjunctiva. Midway through the trial, to reduce the likelihood
of endophthalmitis, the surgical procedure was modified by the
addition of prophylactic intravitreal injections of antibiotics (0.1
ml intravitreal vancomycin [1 mg/0.1 ml] and ceftazidime [2.25
mg/0.1 ml]) at the end of the implant procedure.
After surgery, the following medications were administered per
protocol: 500 mg ciprofloxacin twice daily for 7 to 14 days, 1 drop
gatifloxacin 4 times daily for 7 to 14 days, 60 mg daily prednisolone (orally) for 2 weeks, immediately followed by a methylprednisolone (Medrol; Pfizer, Inc., New York, NY) taper pack (8
mg), until the pack was completed (or equivalent taper of prednisolone), 1 drop Pred Forte (Allergan, Inc., Irvine, CA) 1% 4
times daily for 2 weeks, and 1 drop daily atropine 1% for 2 weeks.
Clinical Evaluation
Subjects were evaluated on day 1, weeks 1, 2, and 4, and months
3, 6, 9, 12, 18, 24, 30, and 36. At each of these follow-up time
points, complete eye examinations (including measurement of
intraocular pressure [IOP]), retinal fundus photography, fluorescein angiography, and optical coherence tomography were
performed.
Serious device- or surgery-related events were reported to the
relevant competent authorities and ethics committees in accordance with the local reporting requirements. During the trial, all
adverse events were subject to detailed review by an independent
medical safety monitor, both as individual events and collated
data.
Subjects were allowed to use the system outside the outpatient
clinical setting in their daily lives after it was individually programmed and they had completed training (usually after the first
month after implantation).
Full-field Stimulus Light Threshold
Subjects’ residual native light perception (i.e., without the use of
the prosthesis) was measured before and after implantation using
the following protocol. The subjects’ eyes were dilated and dark
adapted for 30 minutes. Monocular thresholds were obtained by
patching the other eye during testing. Dark-adapted light thresholds of implanted and fellow eyes to full-field white light stimuli
were measured using the Espion D-FST test within the commercially available E2 clinical electrophysiology software package
(version 5.0; Diagnosys LLC, Littleton, MA). In one center,
Humayun et al 䡠 Second Sight’s Visual Prosthesis International Trial
perform tasks both indoors and outdoors are available at http://
aaojournal.org).
Electrode Reliability
Although all microelectrode arrays comprised 60 electrodes, the
number of enabled electrodes (i.e., electrodes available for stimulation) in the delivered, finished device in this clinical trial varied
from 46 to 60 because of a conservative policy of shutting off
electrodes that did not meet stringent electrical stimulation criteria.
The median number of enabled electrodes at the time of implant
was 55. After implantation, impedance measurements on each
electrode were used to determine if additional electrodes should be
disabled or if previously disabled electrodes should be re-enabled.
Figure 1. A, Photograph of the external portion of the Argus II prosthesis
system (Second Sight Medical Products, Inc., Sylmar, CA) including
glasses-mounted video camera, radio-frequency (RF) coil, and video processing unit (VPU) with rechargeable battery. B, Photograph of the
implanted portion of Argus II prosthesis system including the 6⫻10
electrode array, electronics case, and implant RF coil.
custom-written software was used to obtain full-field stimulus
testing thresholds.15,16 Further details are provided in Appendix 2
(available at http://aaojournal.org). Subjects at sites without an
Espion system or with no measurable threshold below the maximum luminance provided by the system were tested for having
residual bare light perception (BLP) using a photographic camera
flash (Uniblitz 82ABSZ; Vincent Associates, Rochester, NY). This
method used a forced-choice paradigm with 20 blocks, with 4
presentations per block. A 95% significance criterion was used to
determine if a subject was BLP (i.e., ⱖ9/20 correct blocks).
According to the binomial distribution, given a chance rate of 0.25,
the probability (P) of scoring 9 or more correct of 20 by chance is
less than 0.05.
Outside Outpatient Clinic Use
An important objective in the months after implantation was to
have the subjects start using their system outside the outpatient
clinical setting. As soon as possible after implantation, subjects
were trained to set up and use the system independently and to
respond to audible alarm states (e.g., low battery alarm). Subjects
also were trained to use the system to perform activities of daily
living (Videos 1 and 2 showing subjects using their systems to
Figure 2. A, Fundus photograph of implanted Argus II array (Second
Sight Medical Products, Inc., Sylmar, CA) in the macular region. The
electrode array is secured to the retina with a retinal tack; the white square
visible on the distal side of the array is an opaque section of tubing
(the handle) used by the surgeon to position the array. B, Optical coherence tomography image of an implanted Argus II array. Shadows cast on
the retinal image (white arrows) are the result of occlusion of the scanning
light source by the metal electrodes.
3
Ophthalmology
Volume xx, Number x, Month 2011
Tests of Visual Acuity and Real-World Usefulness
Three types of visual acuity tests were performed using computer
monitors. In square localization, subjects were asked to localize a
white square on a black background; in direction of motion,
subjects were asked to indicate the path of a white line swept
across a black background; and in grating visual acuity, subjects
were asked to differentiate the orientation of black and white
bars of a range of widths. Two types of real-world utility tests
were performed. In the door test, subjects were asked to find a
door across a room, and in the line test, subjects were asked to
follow a white line on the floor. For further details on these
testing methods, please see Appendix 2 (available online at
http://aaojournal.org).
Results
Surgery
If the subjects’ eyes did not have equal visual acuity at baseline,
implantation was performed in the worse-seeing eye. If the subjects’ eyes had equal visual acuity, the right eye was selected for
implantation. Twenty-six subjects were implanted in the right eye,
and 4 were implanted in the left eye.
During the implantation procedure, 67% of subjects had their
natural lens removed via clear cornea phacoemulsification (with
the exception of pars plana lensectomy in 2 cases) and they were
left aphakic (no lens). Patients with lens implants (i.e., pseudophakic) did not undergo lens explantation with the exception of 1
patient in whom the intraocular lens was subluxed before surgery,
necessitating its removal. The width of the sclerotomy where the
cable was inserted averaged 5.0⫾0.5 mm (range, 4.5– 6.0 mm).
Fifty-seven percent of subjects had a well-adhered posterior hyaloid, an epiretinal membrane that required peeling, or both. Most
subjects had an allograft (either Tutoplast sclera [57%] or Tutoplast pericardium [30%]) placed over the extraocular portion of the
device (under the conjunctiva) at the end of the surgery. France
does not permit the use of these allografts, so the subjects in France
received either a polytetrafluoroethylene patch (1 subject) or an
autologous aponeurosis graft (3 subjects).
The median implant surgery time was 4 hours and 4 minutes
(range, 1 hour 53 minutes– 8 hours 32 minutes). The longest
implant procedure was prolonged by the fact that the subject had
undergone several previous surgeries on the implanted eye (prior
pars plana vitrectomy to clear vitreous debris and subconjunctival
placental injections), which resulted in extensive conjunctival scar-
ring. In addition, this subject’s lateral rectus muscle was fibrosed
and disinserted in these prior surgeries and required reinsertion.
Figure 2A shows a fundus photograph of an implanted array, and
Figure 2B shows an optical coherence tomography image of an
implanted array.
Clinical Safety
Serious Adverse Events. Serious adverse events (SAEs) were
defined according to ISO 14155 as medical occurrences that either
caused death; were life threatening; caused permanent impairment
of a body function or permanent damage to body structure, or
necessitated medical or surgical intervention to preclude such
impairment or damage; required hospitalization or prolonged hospitalization; or caused fetal death or abnormality (although pregnancy was an exclusion criterion). There were 17 SAEs that were
determined to be device or surgery related as of March 1, 2010.
Table 1 presents a summary of these events. The SAEs often were
clustered (i.e., more than 1 event occurred in the same subject),
and 70% of subjects did not experience any SAEs.
The vast majority of SAEs occurred within the first 6 months
after implantation. Eighty-two percent (14/17) of SAEs occurred
within the first 6 months after implantation, and 70% (12/17)
occurred within the first 3 months after implantation. Subjects
enrolled later in the study experienced fewer SAEs (n ⫽ 4 SAEs
in 2 subjects) than those enrolled earlier in the study (n ⫽ 13
SAEs in 7 subjects). This improvement was attributed to improvements in the surgical technique and minor design improvements
made midway through the study.
Conjunctival erosion and dehiscence over the extraocular implant, when combined, were the most common occurrences and
were treated in all but 1 subject with additional sutures, placement
of additional tissue (conjunctiva or sclera), or both. In 1 subject,
the suture tab on the device was damaged during the repair,
precluding the ability to restore the device; after recurrent erosions,
this device was explanted without any further complications.
Culture-negative presumed endophthalmitis occurred and resolved in 3 subjects in the first group of 15 subjects. None of the
cases were associated with observed pre-existing conjunctival erosion or hypotony. All cases were treated with intravitreal (0.1 ml
vancomycin [1 mg/0.1 ml] and ceftazidime [2.25 mg/0.1 ml])
subconjunctival, topical, and systemic antibiotics.
The first endophthalmitis case developed in the very immediate
postoperative period in a subject from a United States site. The
subject was treated with intravitreal vancomycin and ceftazidime
as well as oral tablets of moxifloxacin. At week 1, antibiotics
(moxifloxacin tablets and topical gatifloxacin) were tapered and
Table 1. Serious Adverse Events (Device or Surgery Related)
All Subjects (n ⴝ 30)
4
Last Subjects
Enrolled in
Study (n ⴝ 15)
Serious Adverse Events
No. of Subjects
with Event
95% Confidence
Interval
No. Subjects
with Event
Conjunctival dehiscence
Conjunctival erosion
Presumed endophthalmitis
Hypotony
Retack
Rhegmatogenous retinal detachment
Tractional retinal detachment
Retinal tear
Inflammatory uveitis
3
2
3
3
2
1
1
1
1
2.1%–26.5%
0.8%–22.1%
2.1%–26.5%
2.1%–26.5%
0.8%–22.1%
0.1%–17.2%
0.1%–17.2%
0.1%–17.2%
0.1%–17.2%
1
0
0
1
1
1
0
0
0
Humayun et al 䡠 Second Sight’s Visual Prosthesis International Trial
Pred Forte (prednisolone acetate) was given over the next week.
The second and third endophthalmitis cases developed approximately 5 and 8 weeks after surgery. These subjects were implanted
at the same center in the United Kingdom on the same day. The
first of these subjects was treated with intravitreal injections of
amikacin and vancomycin, topical application of chloramphenicol
and dexamethasone, and oral tablets of moxifloxacin. The final
subject with endophthalmitis was treated with intravitreal vancomycin, ceftazidime, and amphotericin B. Although the second and
third subjects were implanted at the same center on the same day,
the intravitreal antibiotics chosen for the second subject were
different from the third. The principal investigator consulted with
the infectious disease specialist, who recommended the use of
ceftazidime instead of amikacin and the addition of an antifungal.
The subject also continued oral tablets of moxifloxacin and prednisolone, as well as topical chloramphenicol and dexamethasone.
Four days later, the subject received a second round of intravitreal
vancomycin and ceftazidime.
None of the presumed endophthalmitis cases required explantation of the device, and none occurred in subjects implanted later
in the trial (the last 15 subjects) after a protocol change was
implemented that included prophylactic intravitreal antibiotics at
the end of the case.
In the trial, hypotony was defined as IOP of less than 5 mmHg
that persisted for more than 2 weeks or for shorter duration if the
low IOP was associated with appositional choroidals or with a flat
anterior chamber. Three subjects had hypotony that required surgical intervention. Of these 3 cases, 2 occurred within the first 6
months (at 1 and 4 months) of implantation and the third occurred
at 1 year in the patient whose suture to secure the implant had
broken and whose device had migrated anteriorly. As described
previously, this third subject’s device eventually was explanted,
which led to normalization of the IOP. Of the other 2 subjects, 1
was treated with intraocular silicone oil tamponade, which normalized the IOP. The second had an associated rhegmatogenous
retinal detachment requiring repair; the subject later was treated
with silicone oil tamponade, which resulted in stabilization of the
IOP between 6 and 7 mmHg.
Two cases of retinal detachment, which eventually required
surgical intervention to treat, occurred during the 5 to 6 months
after implantation. The first had a rhegmatogenous detachment
associated with 360 circumferential bands and choroidal effusion;
this is the same subject described above. At approximately 5
months after surgery, a second subject incurred blunt trauma to the
implanted eye, resulting in proliferative vitreoretinopathy that progressed to a tractional retinal detachment. The retinal detachment
was repaired successfully with vitrectomy, partial retinectomy, and
silicone oil.
Two subjects required the array to be retacked to the retina
shortly after the implant surgery. In both cases, it became apparent
in the first few days after surgery that the tack was not implanted
securely at the time of the initial surgery. In both cases, the tack
was reattached successfully near the same retinal site.
Nonserious Adverse Events. Nonserious adverse events (nonSAEs) were those events related to the device or surgery that did
not require surgical intervention (they resolved after treatment
with topical or oral medications or did not require any treatment).
Conjunctival edema that was considered to be more extensive or
lasting longer than what is seen typically after surgery occurred in
10 subjects and was considered a non-SAE. The following nonSAEs occurred in 5 to 7 subjects: intraocular inflammation, hypotony without significant choroidal detachments, suture irritation,
and ocular pain (mostly foreign body sensation). The following
non-SAEs occurred in 2 to 3 people: inflammatory conjunctivitis,
corneal filaments, epiretinal membrane, high IOP controlled by
topical antiglaucoma medications, epiphora, mild hyphema, in-
flammatory uveitis with few keratic precipitates, and mild vitreous
hemorrhage. The following non-SAEs had only a single occurrence and resolved: limited conjunctival dehiscence, corneal abrasion, mild peripheral corneal vascularization, cystoid macular
edema, decrease in light perception, dry eye, transient headache,
iris vessel engorgement that receded secondary to surgery to
resuture sclerotomy (to treat hypotony), a stable tractional retinal
detachment, transient nausea, transient increased nystagmus, scleritis, and transient vertigo.
Full-field Stimulus Light Threshold
Across all subjects measured, there was no significant difference
between threshold obtained before and after surgery for both
implanted and fellow eyes (P⬎0.05, student 2-tailed, paired t test).
All but 1 subject had BLP in both eyes before implantation. The 1
subject who had no light perception recorded in 1 eye before
implantation subsequently was categorized as BLP in that eye after
implantation, when the photographic flash test was available.
Ninety-three percent of subjects still had BLP in both eyes as of
the latest follow-up time point (as of November 30, 2010). Of the
2 whose vision declined from BLP to no light perception, 1
showed the decline in both eyes, and 1 declined only in the
nonimplanted eye. For subjects with quantifiable light thresholds
in both eyes, implanted and fellow eye thresholds were correlated
(R2 ⫽ 0.41; P⬍0.01), thus providing validation of method.
Outside Outpatient Clinical Use
Subjects took the system home at an average of 2.3⫾0.7 months
after implantation (range, 1.4 –3.7 months; median, 2.1 months).
As of March 1, 2010, 29 of 30 subjects were using the system at
home (1 subject’s device was explanted as described above), and
subjects had been using their systems at home for an average of
15.8⫾9.7 months (range, 4.2–28.8 months; median, 14.3 months).
Electrode Reliability
The implants are designed with an electrode array that contains 60
electrodes arranged in a rectangular grid of 6⫻10. Of the electrodes that were enabled at the time of implantation, 94.4% remained enabled and functional throughout the study (as of March
1, 2010).
Perception Thresholds for Electrical Stimulation
All subjects (100%) were able to perceive light when their systems
were stimulated (thresholds were measurable on at least 1 electrode). An average of 55.5% (standard deviation, 32.0%) of all
enabled electrodes across subjects had measurable thresholds of
less than a charge density of 1.0 mC/cm2.
Square Localization
Figure 3 shows the mean distance from the center of the target
(accuracy) for system on and off for each subject at the latest
follow-up time point (the smaller the mean distance, the closer the
subject’s response was to the target). These data show that, as of
the most recent follow-up time point, 27 of 28 subjects (96%)
performed this test better with the system on versus off, and no
subjects performed significantly better with the system off.
Direction of Motion
Figure 4 shows the mean response error (stimulus angle minus the
response angle) with the system on and off for each subject at the
5
Ophthalmology
Volume xx, Number x, Month 2011
Figure 3. Graph showing the mean accuracy on the square localization
task for each subject, system on (filled diamonds) and off (open squares).
Subjects are ordered along the x-axis from greatest difference between on
and off performance to least difference. Error bars indicate standard error.
Asterisks indicate subjects for whom the mean system on performance was
significantly different from the mean system off performance (P⬍0.05,
2-tailed t test assuming unequal variances). Data are the latest available for
each subject as of March 1, 2010.
latest follow-up time point (the smaller the mean response error,
the closer the subject’s response was to the stimulus direction).
These data show that 16 of 28 subjects (57%) performed this test
better with the system on versus off.
Grading Visual Acuity
Per the protocol inclusion criteria, all subjects’ visual acuity was
measured at worse than 2.9 logMAR— off the acuity scale used for
this test—in both eyes before implantation (at month 0). To date,
none of the subjects have been able to score reliably on the visual
acuity scale in either eye with the system off. Seven subjects have
been able to score reliably on the scale (with visual acuity between
2.9 and 1.6 logMAR) with the system on. The best result to date
is 1.8 logMAR (Snellen equivalent, 20/1262). Note that, these tests
were performed without magnification or zoom.
thesis System. There are no other suitable retinal prostheses
with which the safety or efficacy of this system can be
compared. Although other retinal prostheses currently are
being developed by both commercial and academic entities,
none of these devices are commercially approved, none are
approved for longer than 1 month’s implantation, few are
even being subject to clinical trial testing, and none have
been the subject of published long-term clinical results or
multicenter data. However, there are other commercially
available ophthalmic devices that have some similar characteristics (e.g., extraocular or intraocular components, requirement for vitrectomy to install, among others) as this
system. But even in this comparison, the adverse event rates
quoted are reflective of rates for established and practiced
therapies; the rates of adverse events for these same therapies at the time they were introduced to the market (similar
to this device at this stage) likely would have been higher.
As an example, to help evaluate the incidence of conjunctival erosion in prosthesis subjects, glaucoma drainage
devices (or shunts) are a potentially useful comparator device because, like this system, they have an intraocular and
extraocular portion and have a portion of similar volume
implanted under the conjunctiva. Studies conducted by Lankaranian et al17 and Gedde et al18 report the rate of conjunctival erosion of glaucoma drainage devices as 5% to
16%. Gedde et al reported that wound dehiscence also
occurred at a rate of 11%. In this trial, there were 2 cases of
conjunctival erosion (6.7%) and 3 cases of conjunctival
dehiscence (10.0%), which are within the range of those
seen with glaucoma drainage devices.
The incidence of presumed endophthalmitis was 10% (3
of 30) and occurred within 2 months after implantation. In
all 3 subjects, clinical symptoms were reported and signs of
endophthalmitis were observed, although no positive cul-
Orientation and Mobility
The observed results at each time point for the on-versus-off
conditions are shown in Figures 5 and 6 for the door and line tasks,
respectively. A repeated measures analysis of variance model was
used to compute and compare the difference between the mean
success rates (over all subjects) for the door task with the system
on and off at each follow-up time point. These results are provided
in Tables 2 and 3. This analysis demonstrated that, with the
exception of the 12-month time point, subjects’ performance on
the door test was significantly better with the system on compared
with the system off (P⬍0.05; indicated with asterisks). This analysis demonstrated that subjects’ performance on the line task with
the system on was significantly better (P⬍0.05; indicated with
asterisks) than it was with the system off at all follow-up time
points.
Discussion
This study represents 45.6 cumulative subject-years in 30
human subjects implanted with the Argus II Retinal Pros-
6
Figure 4. Graph showing the mean response error for each subject on the
direction of motion task, system on (filled diamonds) and system off
(empty squares). Subjects are ordered along the x-axis from greatest
difference between on and off performance to least difference. Single
asterisks indicate subjects for whom the system on mean was significantly
different (smaller) than the system off mean, and the double asterisk
indicates a subject for whom system off was significantly different (smaller)
than system on (P⬍0.05, 2-tailed t test assuming unequal variances). Data
are the latest available for each subject as of March 1, 2010.
Humayun et al 䡠 Second Sight’s Visual Prosthesis International Trial
Figure 5. Bar graph showing the average percent success at each clinical visit for the find-the-door orientation and mobility task.
tures were identified and all 3 patients demonstrated resolution. Although a comprehensive investigation was conducted for each incidence of presumed endophthalmitis, no
conclusive source of infection could be determined. Potential contributing factors included slightly longer surgical
times than average in these cases and a greater-than-usual
number of personnel moving in and out of the operating
room, some of whom did not wear face masks. Typically,
the incidence of postsurgical endophthalmitis in ophthalmic
procedures is low because of the sterile surgical technique.
The literature reveals an endophthalmitis rate of 1% to 5%
of subjects with glaucoma drainage devices.18,19
With the addition of a temporary sleeve to cover the
array region before it is introduced intraocularly; stricter
sterile techniques during implantation procedures, especially in the handling of the implant; reduction in the number of observers present; and the routine use of prophylactic
intraoperative broad-spectrum antibiotics, the risk of endophthalmitis has been reduced. In fact, no cases of endophthalmitis were observed after these procedural changes (n ⫽
15 cases). None of these subjects’ implants were explanted
and that all remained functional after the presumed endophthalmitis events were treated with antibiotics. The presumed endophthalmitis cases occurred early (within 2
months after implantation) and were not associated with
conjunctival erosions, so it is not likely that the conjunctival
erosions led to the infections, as has been seen in glaucoma
filtering procedures. Moreover, there was no pocket of
Figures 6. Bar graph showing the average percent success at each clinical visit for the follow-the-line orientation and mobility task.
7
Ophthalmology
Volume xx, Number x, Month 2011
Table 2. Repeated Measures Analysis of Variance: Door Task
Door Task
Baseline
RM ANOVA difference Not applicable
(on-off) in mean %
success
P value
Not applicable
3 Months* 6 Months*
24%
0.001
27%
0.0001
12
Months
10%
N/S
18
Months*
32%
0.002
24
Months*
48%
0.0004
RM ANOVA ⫽ repeated measures analysis of variance.
Mean percent rates of success with the system; minus the mean percent rate of success with the system off (over
all subjects) at each time point. Means were computed using a repeated measures analysis of variance model as
described in Appendix B. The mean percent differences were tested against 0 for each time point (i.e.,
differences significantly greater than 0 indicate that the outcome was significantly better with the system on
compared with off). Means were significantly different for all time points except at 12 months after implant
(asterisks). Because of different enrollment times and a method change part way through the study (to make the
task more difficult to perform by chance), the 12-month clinical visit consisted of a larger proportion of subjects
using the new (more difficult) method.
localized infection seen either at the scleral entry site of the
cable or around the extraocular device.
In 1 of the 2 subjects (2/30; 6.7%) with retinal detachments, the subject had experienced a blunt trauma to the eye
that most likely caused the retinal detachment. The second subject was young (27 years of age) with very
adherent hyaloid, which led to incomplete vitreous removal from the posterior retina and subsequent tractional
retinal detachment.
Again, it is difficult to find a large clinical trial in which
the surgical procedure is similar to the one required for
implantation of a retinal prosthesis. But in an effort to draw
some comparisons, the following are the results from more
complex procedures with implants. The rate of retinal detachment for sclerally fixated intraocular lenses is reported
to be between 8.5% and 9.5%.20,21 The rate of retinal
detachment with Retisert (Bausch & Lomb, Rochester, NY)
implantation is between 1.5% and 2.2%,22,23 and that with
the Vitrasert (Bausch & Lomb) implant has been reported to
be as high as 13.8%.24 One must consider that the target
subject population for the Vitrasert (AIDS-related cytomegalovirus) carried with it a higher risk of retinal detachment.
Finally, it is worth noting that there were 2 dislodged
retinal tacks in this trial (6.7%). This is comparable with
the percentage of dislodged retinal tacks reported in the
literature (5.3%).25
As discussed previously, the safety profile of the prosthesis, an active implantable device, is encouraging. The
SAE rates are comparable with those of similar implantable
devices, particularly when considering that the comparator
devices are mature, established therapies. Furthermore, in
later enrollees (the second group of 15 subjects), there was
a lower rate of adverse events, suggesting an improving
safety profile even over the course of this study.
The stability of dark-adapted light perception of implanted and fellow eyes speaks to the stable mechanical and
electrical interface between the electrode array and the
underlying retina. Three of the 4 subjects who went from
BLP to no light perception as determined by the photographic flash test did so in both implanted and fellow eyes,
suggesting that the loss in sensitivity may be the result of
the natural time course of disease progression. Note that in
all 4 subjects, the system has remained functional despite
loss of light sensitivity.
Performance data are encouraging: threshold testing
demonstrated that all subjects were able to perceive percepts
when their implant was activated and that they were able to
do this throughout their entire follow-up duration to date.
Reliability of the prosthesis also was high. Over the
follow-up period of this study, all but one device remained
implanted and the vast majority of electrodes (94.4%) remained functional. All subjects who received an implant use
Table 3. Repeated Measures Analysis of Variance: Line Task
Line Task
Baseline
RM ANOVA difference Not applicable
(on-off) in mean %
success
P value
Not applicable
3 Months* 6 Months*
48%
⬍0.0001
45%
⬍0.0001
12
Months*
44%
0.0002
18
Months*
65%
⬍0.0001
24
Months*
42%
0.005
RM ANOVA ⫽ repeated measures analysis of variance.
Mean percent rates of success with the system on minus the mean percent rates of success with the system off
(over all subjects) at each time point. Means were computed using a repeated measures analysis of variance
model as described in Appendix B. The mean percent differences were tested against 0 for each time point (i.e.,
differences significantly greater than 0 indicate that the outcome was significantly better with the system on
compared with off. Means were significantly different at all time points (asterisks).
8
Humayun et al 䡠 Second Sight’s Visual Prosthesis International Trial
their systems outside of outpatient clinical setting. In addition, 96% of subjects can localize high-contrast objects on a
computer screen significantly better with the system on than
off; 57% can detect the direction of motion of a highcontrast bar significantly better with the system on than off;
23% were able to score on a grading visual acuity test; and
subjects performed 2 orientation and mobility tasks significantly better with the system on than off at all but 1 time
point (12 months after implantation for the door task). The
exception was likely the result of the change in method. Part
way through the trial, the task was made harder to perform
by chance (as described in Appendix 2, available at http://
aaojournal.org). Because subjects were implanted over the
course of 2 years, each time point represents a slightly
different population of subjects. Because of the time at
which the method was changed, nearly all of the 14 subjects
represented in the 12 months after implantation time point
were tested with the old method. The corresponding higher
chance rate (reflected in the higher average success rate with
the system off seen in Fig 5) resulted in no significant
difference between on and off performance at this 1 time
point.
In conclusion, the prosthesis system is reliable over the
long term (45.6 subject-years so far in this study) and
provided benefit to implanted subjects during this period.
The data in this report suggest that, on average, prosthesis
subjects have improved visual acuity from light perception
to at least hand movements, with some improving to at least
counting fingers.26,27 These visual acuity data combined
with the safety and other performance results to date
(e.g., da Cruz et al, Invest Ophthalmol Vis Sci ARVO
E-Abstract, 2010) demonstrate the ability of this retinal
implant to provide meaningful visual perception and usefulness to subjects blind as a result of end-stage outer
retinal degenerations.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Acknowledgment. The authors thank Suber Huang, MD, the
independent medical safety monitor for this study.
19.
References
1. MacLaren RE, Pearson RA. Stem cell therapy and the retina.
Eye (Lond) 2007;21:1352–9.
2. Radtke ND, Aramant RB, Petry HM, et al. Vision improvement in retinal degeneration patients by implantation of retina
together with retinal pigment epithelium. Am J Ophthalmol
2008;146:172– 82.
3. Dobelle WH, Mladejovsky MG, Girvin JP. Artificial vision
for the blind: electrical stimulation of visual cortex offers hope
for a functional prosthesis. Science 1974;183:440 – 4.
4. Veraart C, Raftopoulos C, Mortimer JT, et al. Visual sensations produced by optic nerve stimulation using an implanted
self-sizing spiral cuff electrode. Brain Res 1998;813:181– 6.
5. Humayun MS, de Juan E Jr, Dagnelie G, et al. Visual perception elicited by electrical stimulation of retina in blind humans. Arch Ophthalmol 1996;114:40 – 6.
6. Humayun MS, de Juan E Jr, Weiland JD, et al. Pattern
electrical stimulation of the human retina. Vision Res 1999;
39:2569 –76.
7. Rizzo JF III, Wyatt J, Loewenstein J, et al. Methods and
perceptual thresholds for short-term electrical stimulation of
20.
21.
22.
23.
24.
human retina with microelectrode arrays. Invest Ophthalmol
Vis Sci 2003;44:5355– 61.
Humayun MS, Weiland JD, Fujii GY, et al. Visual perception
in a blind subject with a chronic microelectronic retinal prosthesis. Vision Res 2003;43:2573– 81.
de Balthasar C, Patel S, Roy A, et al. Factors affecting
perceptual thresholds in epiretinal prostheses. Invest Ophthalmol Vis Sci 2008;49:2303–14.
Yanai D, Weiland JD, Mahadevappa M, et al. Visual performance using a retinal prosthesis in three subjects with retinitis
pigmentosa. Am J Ophthalmol 2007;143:820 –7.
Caspi A, Dorn JD, McClure KH, et al. Feasibility study of a
retinal prosthesis: spatial vision with a 16-electrode implant.
Arch Ophthalmol 2009;127:398 – 401.
Greenwald SH, Horsager A, Humayun MS, et al. Brightness as a function of current amplitude in human retinal
electrical stimulation. Invest Ophthalmol Vis Sci 2009;50:
5017–25.
Horsager A, Greenwald SH, Weiland JD, et al. Predicting
visual sensitivity in retinal prosthesis patients. Invest Ophthalmol Vis Sci 2009;50:1483–91.
Oyster CW. The Human Eye: Structure and Function. Sunderland, MA: Sinauer Associates; 1999:660.
Roman AJ, Schwartz SB, Aleman TS, et al. Quantifying rod
photoreceptor-mediated vision in retinal degenerations: darkadapted thresholds as outcome measures. Exp Eye Res 2005;
80:259 –72.
Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG. Fullfield stimulus testing (FST) to quantify visual perception in
severely blind candidates for treatment trials. Physiol Meas
2007;28:N51– 6.
Lankaranian D, Reis R, Henderer JD, et al. Comparison of
single thickness and double thickness processed pericardium patch graft in glaucoma drainage device surgery: a
single surgeon comparison of outcome. J Glaucoma 2008;
17:48 –51.
Gedde SJ, Schiffman JC, Feuer WJ, et al; Tube Versus Trabeculectomy Study Group. Three-year follow-up of the Tube
Versus Trabeculectomy Study. Am J Ophthalmol 2009;148:
670 – 84.
Ang GS, Varga Z, Shaarawy T. Postoperative infection in
penetrating versus non-penetrating glaucoma surgery. Br J
Ophthalmol 2010;94:1571– 6.
Bading G, Hillenkamp J, Sachs HG, et al. Long-term safety
and functional outcome of combined pars plana vitrectomy
and scleral-fixated sutured posterior chamber lens implantation. Am J Ophthalmol 2007;144:371–7.
Kim SW, Kim MJ, Yang KS, et al. Risk factors for pseudophakic retinal detachment after intraocular lens scleral
fixation with or without pars plana vitrectomy. Retina 2009;
29:1479 – 85.
Jaffe GJ, Martin D, Callanan D, et al; Fluocinolone Acetonide
Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020 –7.
Pavesio C, Zierhut M, Bairi K, et al; Fluocinolone Acetonide
Uveitis Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in
noninfectious posterior uveitis. Ophthalmology 2010;117:
567–75.
Kappel PJ, Charonis AC, Holland GN, et al; Southern California HIV/Eye Consortium. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis. Ophthalmology 2006;113:673– 83.
9
Ophthalmology
Volume xx, Number x, Month 2011
25. Abrams GW, Williams GA, Neuwirth J, McDonald HR. Clinical results of titanium retinal tacks with pneumatic insertion.
Am J Ophthalmol 1986;102:13–9.
26. Lange C, Feltgen N, Junker B, et al. Resolving the clinical
acuity categories “hand motion” and “counting fingers” using
the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin
Exp Ophthalmol 2009;247:137– 42.
27. Bach M, Wilke M, Wilhelm B, et al. Basic quantitative assessment of visual performance in patients with very low
vision. Invest Ophthalmol Vis Sci 2010;51:1255– 60.
Footnotes and Financial Disclosures
Originally received: March 10, 2011.
Final revision: September 14, 2011.
Accepted: September 15, 2011.
Available online: ●●●.
Employee - an institution that receives funds from Second Sight Medical
Products, Inc.
Manuscript no. 2011-408.
Jessy D. Dorn - Employee and Equity owner - Second Sight Medical
Products, Inc.
1
Doheny Eye Institute, University of Southern California, Los Angeles,
California.
2
Second Sight Medical Products, Inc., Sylmar, California.
Robert J. Greenberg - Employee and Equity owner - Second Sight Medical
Products, Inc.
3
Aries Arditi - Consultant - Second Sight Medical Products, Inc.; Employee an institution that receives funds from Second Sight Medical Products, Inc.
4
Artur V. Cideciyan - Employee - an institution that receives funds from
Second Sight Medical Products, Inc.
Moorfields Eye Hospital, NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom.
Lions Vision Research and Rehab Center, Johns Hopkins University,
Baltimore, Maryland.
5
Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France.
6
Manchester Royal Eye Hospital, Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.
7
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
8
University of California, San Francisco, San Francisco, California.
9
Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston,
Massachusetts.
10
Retina Foundation of the Southwest, Dallas, Texas.
11
Wills Eye Hospital, Philadelphia, Pennsylvania.
12
Centro de Retina Medica y Quirúrgica, SC, Escuela de Medicina, Tec de
Monterrey Campus Guadalajara, Guadalajara, Mexico.
13
Hôpitaux Universitaires de Genève, Geneva, Switzerland.
14
Lighthouse International, New York, New York.
15
Columbia University, New York, New York.
The members of the Argus II Study Group are listed in Appendix 1
(available online at http://aaojournal.org).
Financial Disclosure(s):
Mark S. Humayun - Equity owner - Second Sight Medical Products, Inc.;
10
Lyndon da Cruz - Employee - an institution that receives funds from
Second Sight Medical Products, Inc.
Gislin Dagnelie - Employee - an institution that receives funds from
Second Sight Medical Products, Inc.
Dean Eliott - Employee - an institution that receives funds from Second
Sight Medical Products, Inc.
Eugene Filley - Employee - an institution that receives funds from Second
Sight Medical Products, Inc.
Avinoam B. Safran - Employee - an institution that receives funds from
Second Sight Medical Products, Inc.
José-Alain Sahel - Employee - an institution that receives funds from
Second Sight Medical Products, Inc.
Supported by the National Institutes of Health, Bethesda, Maryland (grant
no.: 5R01EY012893-10 [RJG]). Sponsored by Second Sight Medical Products, Inc., Sylmar, California. The sponsor participated in the design of the
study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, and review of the manuscript.
Correspondence:
Mark S. Humayun, MD, PhD, DVRC 117, 1355 San Pablo Street, Los
Angeles, CA 90033. E-mail: humayun@usc.edu.